Work

Improving CD123-Targeted T-Cell Therapy for Acute Myeloid Leukemia

Year: 2018

Type: article

Abstract: Background: Adoptive immunotherapy, using CD123 Engager (CD123-ENG) T-cells, has shown success in preclinical studies, recognizing and killing acute myeloid leukemia (AML) blasts in vitro and in vivo. CD123-ENG T-cells secrete bispecific molecules that recognize CD3 (T-cells) and CD123 (AML blasts), and are able to direct transduced T-cells and recruit bystander T-cells to kill CD123-positive blasts. However, CD123-ENGs do not provide costimulation. We are seeking to improve the expansion, persistence and sequential killing capabilities of CD123-ENGs by genetically modifying these cells with an inducible costimulatory molecule, which can be activated by a chemical inducer of dimerization (CID).

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2017.12.214